학술논문
RIBANNA Real-world evidence of ribociclib plus aromatase inhibitor, or endocrine monotherapy, or chemotherapy as first-line therapy for postmenopausal women with HR+, HER2 advanced breast cancer (aBC)
Document Type
Journal
Author
Source
Subject
Language
English
ISSN
15387445